Background We previously reported on a Swedish patient with Behçet's disease (BD) who was an ultra-rapid metaboliser of drugs catalysed by CYP2C9. Was this extreme metabolism caused by the disease? Aim This study aims to compare the genotype/phenotype of CYP2C9 in patients with BD and healthy subjects. As the occurrence of BD is high in Turkey, all subjects were recruited from this country. Methods Genotyping of CYP2C9 was performed using standard PCR-RFLP and allele-specific PCR methods. Phenotyping of CYP2C9 was performed by administration of a 50-mg single oral dose of losartan and by calculating the urinary metabolic ratio (MR) of probe drug to its metabolite E-3174. Quantitation was performed by HPLC. Results The frequency of CYP2C9*2 and *3 was not significantly different between the Behçet's disease patients (12.5 and 8.7 %) and the healthy subjects (8.9 and 8.2 %). The geometric mean losartan MR was higher in the 52 patients (1.75) than in the 96 healthy subjects (1.02) (p=0.002; t-test). Within the genotypes *1/*1, there was a significant difference of MR between patients and healthy subjects (P=0.006). All but three of the Behçet's disease patients were treated with colchicine. In nine subsequent patients, we found no significant effect of 2 weeks of treatment with colchicine on the CYP2C9 MR. Conclusion Contrary to expectation, the CYP2C9 activity was lower in Turkish BD patients compared to healthy subjects. As this seems not to be due to colchicine treatment, our hypothesis is that inflammation related to BD might have caused the down-regulation of the CYP2C9 activity due to immune cytokine reactions. The ultra-rapid metabolism of CYP2C9 substrate drugs in the Swedish patient was not due to her BD.
Introduction
A case of an ultra-rapid metaboliser of CYP2C9 substrate drugs was previously reported in Sweden [1] . The patient did not carry any functional genetic variation in her CYP2C9 exons and promoter regions [2] and at the same time had Behçet's disease (BD). In continuation to looking for the molecular mechanism of why this patient had a very rapid metabolism Mustafa Tugrul Goktaş and Fazleen Hatta contributed equally to this work.
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of phenytoin and losartan, we now explore the possibility of an ultra-high CYP2C9 activity being a result of BD.
BD is a multisystem, chronic-relapsing, inflammatory disorder most predominantly found in Turkey. It is also found in Japan, China, the Mediterranean and the Middle East, leading to the theory that the disease may have genetically spread centuries ago along the ancient silk trade route [3] [4] [5] [6] . The high occurrence of BD in Turkey provides the platform to this study.
The aetiopathogenesis of BD is yet to be fully uncovered. BD is typically characterised with chronic relapsing oral-genital ulcers and uveitis [7] . The disease is associated to the articular, gastrointestinal, cardiopulmonary, neurologic, and vascular systems, but the involvement of immunogenetics, immune regulation, vascular abnormalities, or bacterial and viral infection may contribute to its development [7] .
Colchicine has been part of BD treatment regimen since its first use in 1977 to reduce the symptoms of inflammation and arthritis [8, 9] . It has been shown that colchicine downregulates the activity of cytochrome P450 enzymes, especially CYP2B6, CYP2C8, CYP2C9, and CYP3A4 in human hepatocytes [10] . However, the effect of colchicine on these human enzymes in vivo is yet to be reported.
The distribution of CYP2C9 genotype among Turkish healthy subjects and their losartan metabolic profile have been previously reported [11] . In addition, another group also localized in Turkey has published that there is no relation of CYP2C9 genotype to Behçet's disease when compared to healthy subjects [12] . Our present study will compare the CYP2C9 phenotypes in addition to the genotypes between Turkish healthy subjects and BD patients and find conclusion for our initial objective of finding out if ultrarapid metabolism of CYP2C9 is caused by BD, as seen in our previously reported Swedish BD patient [1] .
Recently, a study by Liang et al. has shown that BD patients have a significant increase in their peripheral Th17-related cytokines (IL-6, IL-17, IL-23 and TGF-β1) compared to healthy individuals [13] . Other studies have previously demonstrated that the increased levels of acute-phase proteins concurrently downregulate liver-specific proteins involved in drug metabolism, especially the activity of cytochrome P450 enzymes [14] [15] [16] . For example, the study by Aitken and Morgan has shown that increased concentrations of cytokines IL-6 and TGF cause a significant decrease of 30 to 50 % in mRNA expression of CYP2C9 and CYP2C19 in human hepatocytes [16] . Overall, our aim was to investigate the influence of BD, genotype and colchicine treatment on the activity of CYP2C9 in a Turkish population.
Subjects and methods
The BD patients were recruited in the Department of Rheumatology at Hacettepe University Hospital, Ankara, Turkey. Patients and healthy subjects were included after being informed about the study and had given their consent. All of the healthy subjects were consenting adults who are not taking any other medication and comply with the inclusion and exclusion criteria as described and applied in the previous study [11] . Approval to conduct this study was granted by the Local Ethics Committee at Hacettepe University (TBK11/14), Ankara. The ethics committee at Karolinska Institutet (KI) approved the analysis of the samples sent to KI in Sweden from Turkey. This study was designed in conformity with the Declaration of Helsinki.
All subjects received a 50-mg single oral dose of losartan, and urine was collected for 8 h after the administration of the drug. In all subjects, losartan was taken just before going to bed. All subjects urinated before taking losartan, and all the urine during the 8 h after drug intake was collected in a container provided by the researchers. The subjects brought this container to the hospital in the morning. Blood samples were taken into tubes with EDTA for DNA extraction. Urine and blood samples were stored at −20°C.
Analysis of losartan and its metabolite in urine
The concentrations of losartan and its metabolite (E-3174) were analysed in urine by high-performance liquid chromatography (HPLC) as described by Babaoglu et al. [11] . Briefly, a 66/34 mixture of phosphate tamponate (NaH 2 PO 4 , 15 mM, pH=2.8) and acetonitrile was used as mobile phase. Urine samples in mobile phase and isopropanol (2/1/1 in volume, respectively) were injected into Agilent Eclipse XDB-C18 (5 μm, 4.6 × 150 mm) column via Agilent Technologies 1200 HPLC system (Agilent Technologies, Waldbron, Germany). Losartan and E-3174 were detected via a UV detector at 245 nm. The inter-and intra-day coefficient of variation (CV) was less than 4 % for losartan and its metabolite. The ratio of losartan to its metabolite (E-3174) was calculated (metabolic ratio, MR) and used as a marker of the activity of the CYP2C9 enzyme. Data were analysed on 'ChemStation for LC Systems Release B.03.01.317' (Agilent Technologies, Waldbron, Germany) software.
Genetic analysis of CYP2C9 *2 and *3 DNA was isolated from the blood samples with QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). The CYP2C9*2 and 2C9*3 variants that are responsible for a reduced CYP2C9 activity were analysed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (PCR-RFLP) methods as described by Yasar et al. [17] .
Detection of four intronic SNPs
CYP2C9 SNP 1: IVS1+83 T>C (rs9332104), SNP2: IVS2+ 73 T>C (rs9332120), SNP 3: IVS6+95A>G (rs9332174) and SNP 4: IVS8-109A > T (rs1934969) were detected using allele-specific PCR and PCR-RFLP method as published previously [2] . The software Haploview was used to find pairwise linkage disequilibrium (LD) between the four SNPs, CYP2C9*2 and CYP2C9*3 alleles [18] .
Effect of colchicine on MR in nine patients
Nine patients (three with familial Mediterranean fever (FMF), two with BD, two with arthritis, one with osteoarthritis and one with oral aphthous lesions) were recruited to have their losartan MR measured before and after 2 weeks of colchicine treatment. The MR changes were then analysed separately from the large BD patients group.
Statistics
Fischer's exact chi-square test was used to compare the CYP2C9 allele and genotype frequencies. MR in BD patients and healthy individuals were compared with t-test based on log-transformed MR. Paired t-test was used to compare the MR of nine individuals before and during colchicine treatment; p<0.05 was accepted as level of statistical significance. SPSS (version 20.0) (SPSS, Chicago, IL, USA) was used for the statistical comparison.
Results

Subjects' recruitment
Results from 73 of the healthy subjects used in this study are from 85 individuals published in 2004 [11] . Twelve subjects dropped out because DNA was not available when they were going to be genotyped subsequently for the four intronic SNPs included in this study. Together with 52 BD patients, we have now also recruited 23 new healthy subjects. Table 1 shows that there is no significant difference in the losartan/E-3174 metabolic ratios (MR) between the two groups of healthy Turkish subjects that were recruited earlier and the current subjects. This shows that the combined total of 96 subjects may be used as controls and compared to the 52 BD patients.
Fifty-two subjects (24 women, 28 men) fulfilled the criteria of International Study Group for diagnosis of Behçet's Disease (BD), and 96 healthy subjects (47 women, 49 men) without any diagnosed health problem were included in this study. The mean age of the patients was 41.5 (range between 20 and 73) years, their median BMI was 26.2 (BMI range between 18.4 and 33.2), and the mean time after the onset of disease was 10.9 (range between 1 and 43) years. The mean age of the healthy control group was 32.7 (range between 26 and 47) years, and their median BMI was 24.4 (BMI range between 18.8 and 29.7). In a substudy group that consists of nine patients about to be prescribed with colchicine, the mean age was 35 (range between 19 and 60), and their median BMI was 20.9 (BMI range between 16.4 and 23.8).
Losartan MR in Behçet patients and healthy subjects Figure 1 illustrates the logarithmic MR distribution in 52 BD patients and 96 healthy subjects. There is a significant difference in MR between BD patients (1.75) as compared to the healthy subjects (1.02) (p=0.002). All of the Behçet's disease patients were on colchicine with the exception of three individuals.
The colchicine dosages received by the BD patients ranged from 1 to 4 mg/day, with 29 patients receiving 3 mg/day, 11 receiving 2 mg/day, 4 receiving 1 mg/day and 2 patients receiving 4 mg/day.
CYP2C9 genetic polymorphism analysis
The genotype frequencies of CYP2C9 variants and comparison of the distributions between 52 BD patients and 73 healthy individuals are given in Table 2 , and their allele frequencies are shown in Table 3 . Genotypes were not determined in the 23 healthy subjects recently studied. The frequencies of CYP2C9*2 were 12.5 and 8.9 % for BD patients and healthy individuals, respectively. The frequency of allelic Table 1 Comparison of losartan/E-3174 metabolic ratio (MR) between healthy subjects published (Babaoglu et al. 2004 ) and recently studied. The geometric mean MR in the total healthy subjects is compared to the MR of Behçet's disease patients
Group
Number of subjects Geometric mean MR (90 %, CI) p-value variant of CYP2C9*3 was 8.7 % for BD patients and 8.2 % for healthy individuals. CYP2C9*2/*2 and *3/*3 genotypes were not detected in BD patients, and their frequency was 1.4 % among healthy individuals. There is one individual in each group with the *2/ *3 genotype. Referring to Fig. 1 , among the three patients who are not taking colchicine, two were genotyped as *1/*1 (MR= 0.46 and 1.01), and the other was *1/*2 (MR=7.88).
The relation between MR and CYP2C9 genotypes Table 2 (right) compared the MR of the 52 BD patients to the 73 healthy subjects according to their genotypes. The geometric mean MR for CYP2C9 *1/*1 genotype group was 1.34 in the BD patients, whereas in the healthy subjects the MR was lower (geometric mean 0.83; p=0.006). In other genotype groups, no significant differences were found between BD patients and healthy controls ( Table 2) .
In Turkish subjects with CYP2C9*1/*1, no relationships were found between variant alleles SNP1: IVS1+83 T>C, SNP2: IVS2+73 T>C, SNP3: IVS6+95A>G and SNP4: IVS8-109A>T to losartan MR (phenotype) (Pearson's chisquare test, p>0.05 for all genotypes). There is a significant correlation seen for individuals with *1/*2 and SNP1 (p= 0.013, wild type for SNP1 has higher MR), but the number of individuals with mutated alleles is too small (n=2 heterozygous for SNP1 versus n=8 wild-type allele). There is also no linkage found connecting *2 and *3 genotypes of CYP2C9 to the four variants in both groups (Supporting data 1: Fig. 2 ).
Concurrent drugs prescribed to the patients
The comorbidities of patients in the BD group and the colchicine effect group are attached on BSupporting data 2: Table 4^ . The concurrent drugs prescribed to these patients were listed by group in BSupporting data 3: Table 5^ , and their median 
Number of subjects
Losartan/E-3174 raƟo p = 0.002 * Turkish subjects Fig. 1 Comparison of losartan/E-3174 ratio between the Behçet's disease patients and healthy subjects. The three patients in red represent patients who were not on colchicine treatment. MR metabolic ratio. MR = 1 is indicated as an arbitral vertical line. Asterisk Swedish ultrarapid metaboliser with Behçet's disease. MR < 0.13 [1] dosage were given. Among these drugs, one subject was found to be on CYP2C9 inducer carbamazepine at 600 mg daily (with genotype CYP2C9*1/*2 and losartan MR 2.0), and several were on CYP2C9 substrate/inhibitors: warfarin with median dosage of 5 mg daily (eighth individuals), omeprazole 20 mg daily (three individuals) and sertraline 50 mg daily (one individual). In the colchicine effect group, one individual was on metformin 1000 mg daily, gliclazide 160 mg daily, acarbose 300 mg daily, and alendronate sodium once in a week; one individual was on warfarin at 5 mg daily, interferon alpha 6 MU at three times per week and aspirin at 300 mg daily; one individual on one-time 2 mg prednisone; and one individual took one tablet of avmigran® (paracetamol 325 mg, ergotamine tartrate 0.75 mg, caffeine 80 mg, mecloxamine citrate 20 mg).
Most of the patients were on their concurrent drugs while the study was carried out. Exception was in the colchicine effect group where one patient was prescribed prednisone together with colchicine and one patient used avmigran® due to migraine a day before losartan was given.
The effect of colchicine treatment on MR in patients
In nine patients about to be prescribed with colchicine, losartan MR was measured before starting treatment and again after 2 weeks of colchicine treatment. The dosages of colchicine given to the nine patients (four patients received 3 mg/ day, three patients received 2 mg/day and two patients received 1 mg/day) were very similar to those given to our large group of BD patients.
There was no difference in geometric mean MR before (3.00) compared to 2.80 during colchicine (p=0.89, 90 % CI=0.38-3.02). Three patients did not show any change in their MR, three had lower MR during colchicine treatment and three had higher MR.
Discussion
This study shows that BD is not the cause of ultra-rapid metabolism seen in the Swedish patient with BD [1] . The result is in contrary to our expectation, but there is a significant shift of MR from a geometric mean of 1.02 in the healthy subjects to 1.75 in the BD patients showing a lower activity of CYP2C9 in the group of BD patients. We anticipated that this might be due to three possible factors, difference between BD patients and healthy subjects in the genetic polymorphism of CYP2C9, an inhibition of CYP2C9 by the colchicine treatment and a regulation abnormality due to BD.
We found no significant difference in the distribution of genotypes between the healthy subjects and the BD patients. This shows that the CYP2C9 genotype does not influence the susceptibility to Behçet's disease. There is, however, a significant difference in the geometric mean MRs between the two groups when the entire groups of individuals with CYP2C9*1/*1 and CYP2C9*1/*2 were compared. When individuals with other genotypes were compared, no significant difference was observed between the median MRs, probably due to the small sample size of these groups. We have previously reported that variant IVS8-109A>T is related to a lower CYP2C9 activity in Swedes [2] . However, there is no effect of this variant on the MR of the present Turkish population. It is possible that the effect seen in Swedes caused by this variant is due to its link to an important polymorphism in Swedes, but not in the Turkish population.
The initial median MRs for nine patients (geometric mean MR=3.0) before they were given colchicine was similar to our first studied 52 BD patients (geometric mean MR=1.75) and higher than the geometric mean MR of healthy subjects (1.02) shown in Fig. 1 . There was no significant change in MR (p= 0.89) observed during colchicine treatment. This result shows that colchicine given for 2 weeks has little influence on the CYP2C9 activity in these patients. Additionally, among the BD patients, there are three individuals who were not on colchicine (Fig 1) . Two of them carry CYP2C9*1/*1 genotype. The MRs of these two patients were within the MR range of healthy individuals. The third individual with CYP2C9*1/*2 genotype has a higher MR. These results indicate that colchicine has no effect on the CYP2C9 activity.
Behçet's disease is a systemic inflammatory disorder localised in multiple organs of the human body. Several studies have indicated that IL-6 [19] and TGFs [20] have a higher expression in BD patients compared to healthy subjects. It has also been shown that these inflammatory response substances, specifically IL-6 and TGF-β, downregulate the expression of CYP2C9 in vitro [13, 16] and breast cancer patients [21] or on a larger scale, suppressing the biosynthesis of drug-metabolising enzymes [22] . Other studies have also linked lower activity of CYP2C9 to inflammation-related diseases such as rheumatoid arthritis, end-stage renal disease and moderate to severe renal function impairment [22] [23] [24] [25] [26] . The relationship between the cytokines, BD and CYP2C9 is probably the mechanism behind the lower activity of CYP2C9 in BD patients shown in this report. Similarly, patients with inflammatory bowel disease were reported to suffer from impaired detoxification of xenobiotics that are regulated by multiple metabolising agents and enzymes in the gut [27] .
In conclusion, we have found that BD patients might have a lower CYP2C9 enzyme activity compared to the healthy subjects. The release of inflammatory response factors that down-regulate the enzyme expression is likely the cause of this finding. This hypothesis requires further studies to identify the possible factors responsible for the effect. In this study population, we could not show that colchicine has a significant effect on the MR of the BD patients.
There are two major limitations to this study. First, the short period of 2 weeks after taking colchicine may not provide enough time to observe a stable impact of either induction or inhibition of CYP2C9 in the subjects. The second limitation was that the nine patients were treated for different illnesses. The differences in diseases can be justified by mentioning that these patients were all treated with inflammation-related diseases.
This study is of clinical relevance by showing that inflammation may play a significant role in the down-regulation of CYP2C9*1/*1 Behçet's disease patients. The efficacy of some treatments would be compromised in these patients because they were given drugs in dosages that might be ineffective or cause toxicity and adverse drug reaction. We are planning to study the activity of other drug-metabolizing enzymes in Behçet's disease.
